share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4：持股變動聲明-董事 Borgeson Blake
美股sec公告 ·  05/31 06:43
牛牛AI助理已提取核心訊息
Blake Borgeson, a reporting person associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of Class A Common Stock on May 28, 2024. The transaction was carried out in the open market at a price of $9.1677 per share, resulting in a total sale value of approximately $104,942.66. Following the sale, Borgeson's direct holdings in the company amount to 7,186,913 shares of Common Stock.
Blake Borgeson, a reporting person associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of Class A Common Stock on May 28, 2024. The transaction was carried out in the open market at a price of $9.1677 per share, resulting in a total sale value of approximately $104,942.66. Following the sale, Borgeson's direct holdings in the company amount to 7,186,913 shares of Common Stock.
與Recursion Pharmicals, Inc. [RXRX] 相關的申報人布萊克·博格森於2024年5月28日完成了11,447股A類普通股的出售。該交易在公開市場上進行，價格爲每股9.1677美元，總銷售價值約爲104,942.66美元。出售後，博格森在公司的直接持有量爲7,186,913股普通股。
與Recursion Pharmicals, Inc. [RXRX] 相關的申報人布萊克·博格森於2024年5月28日完成了11,447股A類普通股的出售。該交易在公開市場上進行，價格爲每股9.1677美元，總銷售價值約爲104,942.66美元。出售後，博格森在公司的直接持有量爲7,186,913股普通股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。